---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-127004"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T05:19:27.606986+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee doses first healthy volunteers in Phase 1 trial of TSLP antibody APG333

## Summary
- APG333 is a novel half-life extended monoclonal antibody targeting TSLP for asthma, COPD, and I&I conditions.
- Phase 1 trial: double-blind, placebo-controlled, single-ascending dose in ~32 healthy volunteers across 4 cohorts.
- Interim safety and pharmacokinetic data expected in second half of 2025.
- Preclinical proof-of-concept achieved for APG777+APG333 combination; clinical trial planning underway in asthma and COPD.

## SEC filing metadata
- accession: 0001104659-24-127004
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924127004/0001104659-24-127004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924127004/tm2430568d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-127004
- JSON: https://secwatch.observer/filing/0001104659-24-127004.json
- Plain text: https://secwatch.observer/filing/0001104659-24-127004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.